Last updated: February 20, 2026
What is the Drug and Its Approved Indication?
NDC 64380-0155 corresponds to Vasculin, a biosimilar or biosimilar candidate produced by a contract manufacturer. Its primary indication is for vascular disorders such as peripheral vascular disease and associated ischemic conditions. The formulation is typically intravenous, targeting hospital and specialty pharmacy channels.
Market Overview
Market Size
The global vascular disorder treatment market was valued at approximately $3.6 billion in 2022 and is projected to grow at a CAGR of about 5.2% through 2027. Major drivers include increasing prevalence of peripheral artery disease (PAD), diabetes, and aging populations.
Key Competitors
- Epoprostenol (brand: Flolan), used for pulmonary arterial hypertension.
- Iloprost (brand: Ventavis), for pulmonary hypertension.
- Recombinant human thrombopoietin analogs for thrombocytopenia.
Biosimilar competition has intensified, with several products approved or under review by FDA and EMA.
Regulatory Status
- FDA Approval: Pending or recent approval, with market launch expected within 12–18 months.
- EMA Approval: Under review, with potential market introduction in Europe within 12 months of approval.
Distribution Channels
- Hospital formularies
- Specialty pharmacies
- Infusion centers
Pricing Benchmarks
Current Market Prices
| Product |
Indication |
Typical Price per Dose |
Market Segment |
| Flolan |
Pulmonary hypertension |
$12,000–$14,000 |
Hospitals, specialty pharmacies |
| Ventavis |
Pulmonary hypertension |
$8,500–$10,000 |
Specialty pharmacies |
| Biosimilar candidates |
Peripheral vascular diseases |
Expected <$10,000 |
Hospitals, infusion centers |
Biosimilar Price Projections
Based on biosimilar entry patterns in cardiovascular and hematology segments, initial pricing is expected to be 15–25% below reference products. Thus, initial wholesale acquisition costs (WAC) could range from $8,000 to $10,000 per dose.
Factors Influencing Price
- Market penetration: Biosimilars typically lower prices through competition after initial launch.
- Reimbursement policies: CMS and private payers favor biosimilars, increasing uptake.
- Manufacturing costs: Estimated at 30–40% of the WAC, with economies of scale improving margins.
- Regulatory exclusivity: Limited to 12 years in the U.S., influencing initial pricing strategies.
Pricing Trends and Forecasts
- 2023–2024: Launch with WAC at $8,000–$10,000; prices stabilize as market adopts biosimilars.
- 2025–2026: Prices could decline by 10–20% due to increasing biosimilar competition.
- Long-term: Market premiums may stabilize at 10–15% over reference brands, driven by clinical interchangeability and payer preferences.
Market Entry Barriers and Opportunities
Barriers:
- Regulatory hurdles
- Manufacturer capacity constraints
- Reimbursement restrictions
- Physician and hospital adoption inertia
Opportunities:
- Growing prevalence of vascular disorders
- Shift towards biosimilars to reduce treatment costs
- Expanding outpatient infusion services
Strategic Recommendations
- Pricing strategy: Set introductory WAC at $8,000–$9,000 to establish market presence.
- Market access: Collaborate with payers early to facilitate reimbursement.
- Differentiation: Emphasize bioequivalence and safety profile to encourage switching from reference products.
Summary Table: Price Projection Timeline
| Year |
Estimated Price Range (WAC) per Dose |
Market Context |
| 2023 |
$8,000–$10,000 |
Launch phase, initial uptake |
| 2024 |
$7,500–$9,500 |
Increased biosimilar competition |
| 2025 |
$7,000–$9,000 |
Price stabilization |
| 2026 |
$6,500–$8,500 |
Broader market adoption |
Key Takeaways
- NDC 64380-0155’s market depends on the approval timeline and competitive landscape.
- Initial market prices are expected at approximately $8,000–$10,000 per dose.
- Cost reductions are likely within 2–3 years, following biosimilar market entry.
- Reimbursement and hospital adoption will influence pricing and market penetration.
- The growth trajectory aligns with other biosimilars targeting vascular indications, with long-term modest price premiums.
FAQs
1. What factors most influence biosimilar pricing? Reimbursement policies, manufacturing costs, market competition, and clinical interchangeability.
2. How quickly can biosimilars displace reference products? Usually within 2–3 years in hospital infusion markets with supportive reimbursement policies.
3. What are the main barriers to market entry? Regulatory approval, manufacturing capacity, payer acceptance, and clinician adoption.
4. What distinguishes this biosimilar from reference products? Its bioequivalence, safety profile, and cost advantage.
5. How does the prevalence of vascular diseases impact demand? Rising prevalence increases the patient population, boosting the market for vascular therapeutics.
References
- MarketsandMarkets. (2022). Biosimilars Market by Type, Application, and Region – Global Forecast to 2027. [Details of market size, growth rates]
- IQVIA. (2023). The Global Use of Medicines in 2022. [Pricing benchmarks]
- U.S. Food and Drug Administration. (2022). Biosimilars Overview. [Regulatory pathway insights]
- EvaluatePharma. (2022). Oncology and Specialty Market Analysis. [Market adoption trends]
- CMS. (2023). Medicare Part B Drug Payment Policies. [Reimbursement overview]
